Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma

Journal of Nuclear Medicine

Volumn 46, Issue 1 SUPPL., 2005, Pages

  Teunissen, Jaap J M ^a   Kwekkeboom, Dik J ^a   Kooij, Peter P M ^a   Bakker, Willem H ^a   Krenning, Eric P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

177Lu; Differentiated thyroid carcinoma; Octreotate; Radionuclide therapy; Somatostatin receptor

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSYL 3 OCTREOTIDE LUTETIUM 177; LUTETIUM 177; PENTETATE INDIUM IN 113M; PENTETREOTIDE IN 111; SOMATOSTATIN DERIVATIVE; THYROGLOBULIN; UNCLASSIFIED DRUG; (177LUTETIUM DOTA(O)TYR3)OCTREOTATE; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND; PEPTIDE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GAMMA SCINTIGRAPHY; HUMAN; ISOTOPE LABELING; MALE; PRIORITY JOURNAL; RADIATION DOSE; RADIOACTIVITY; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; CARCINOMA; CLINICAL TRIAL; METASTASIS; MIDDLE AGED; SCINTISCANNING; THYROID TUMOR; TUMOR RECURRENCE;

AGED; CARCINOMA; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOMETALLIC COMPOUNDS; PEPTIDES; RADIOPHARMACEUTICALS; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 14844359800     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418-428.
2. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297-306.
3. Cooper DS, Schneyer CR. Follicular and Hurthle cell carcinoma of the thyroid. Endocrinol Metab Clin North Am. 1990;19:577-591.
4. Maxon HR, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am. 1990;19:685-718.
5. Caplan RH, Abellera RM, Kisken WA. Hurthle cell neoplasms of the thyroid gland: reassessment of functional capacity. Thyroid. 1994;4:243-248.
6. Sherman SI. Thyroid carcinoma. Lancet. 2003;361:501-511.
7. Sisson JC, Giordano TJ, Jamadar DA, et al. 131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma. Cancer. 1996;78:2184-2192.
8. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985;56:2155-2160.
9. Droz JP, Schlumberger M, Rougier P, Ghosn M, Gardet P, Parmentier C. Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori. 1990;76:480-483.
10. Postema PT, De Herder WW, Reubi JC, et al. Somatostatin receptor scintigraphy in non-medullary thyroid cancer. Digestion. 1996;57(suppl 1):36-37.
11. Haslinghuis LM, Krenning EP, De Herder WW, Reijs AE, Kwekkeboom DJ. Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest. 2001;24;415-422.
12. Christian JA, Cook GJ, Harmer C. Indium-111-labelled octreotide scintigraphy in the diagnosis and management of non-iodine avid metastatic carcinoma of the thyroid. Br J Cancer. 2003;89:258-261.
13. Stokkel MP, Reigman HI, Verkooijen RB, Smit JW. Indium-111-octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131. J Cancer Res Clin Oncol. 2003;129:287-294.
14. Gorges R, Kahaly G, Muller-Brand J, Macke H, Roser HW, Bockisch A. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid. 2001;11:647-659.
15. 90Y]-DOTA-D-Phe1-Tyr3- octreotide: a pilot study. Nucl Med Commun. 2001;22:673-678.
16. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med. 2002;32:148-155.
17. Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med. 2002;32:110-122.
18. 0]octreotide in patients. 2001;28:1319-1325.
19. Krenning EP, de Jong M, Kooij PP, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999;10(suppl 2);S23-S29.
20. Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging. 2003;30:417-422.
21. Chinol M, Bodei L, Cremonesi M, Paganelli G. Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med. 2002;32:141-147.
22. 90Y-DOTATOC. J Nucl Med. 2002;43:610-616.
23. 111In-DTPA-octreotide therapy in patients with progressive radioiodine non-responsive thyroid cancer: a pilot study. Nucl Med Commun. 2004;25:683-690.
24. 99mTc-EDDA/ HYNIC-TOC and (18)F-FDG in thyroid cancer patients with negative (131)I whole-body scans. Eur J Nucl Med Mol Imaging. 2004;31:330-341.
25. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836-846.
26. Ain KB, Taylor KD, Tofiq S, Venkataraman G. Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab. 1997;82:1857-1862.
27. 111In- DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med. 2000;41:636-642.
28. de Jong M, Breeman WA, Bakker WH, et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res. 1998;58:437-441.
29. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27;273-282.
30. Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30:1338-1347.